ePrize and Curalate Announce Strategic Partnership

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
ePrize and Curalate Announce Strategic Partnership

PLEASANT RIDGE, MI--(Marketwired - Apr 17, 2013) - ePrize , a leader in digital engagement for social, mobile and web campaigns, has partnered with Curalate , the leading marketing and analytics platform for image-centric social media sites, to offer brands customized, user-friendly, sweepstakes and contests on the popular image sharing site, Pinterest. The partnership combines Curalate's proprietary technologies for tracking and powering Pinterest promotions with ePrize's powerhouse platform in creating full scale promotions, loyalty and mobile solutions, bringing a streamlined promotion flow to the marketplace.

"In today's digital landscape, social networking is visual networking. This trend is driving brands to build more awareness and deepen engagement with consumers on Pinterest," said Sara Kowal, VP of Innovation at ePrize. "By partnering with Curalate, we're now able to provide our clients a customizable, multi-channel flow for Pinterest sweepstakes and contests alongside our industry-leading strategic, creative, legal and fulfillment services."

With 70 percent of social media conversations now containing imagery, brands must be aware of, and leverage, picture-based platforms. In fact, according to a 2012 Pew Research report , 15 percent of online adults are Pinterest users. However, despite the site's popularity, Pinterest promotions were previously time consuming for users to enter, and arduous for brands to measure. The new partnership between ePrize and Curalate allows brands to design seamless, measurable promotions that align with social networking objectives, showcases brand-owned content and boosts consumer engagement.

"The popularity of Pinterest demonstrates that consumer behavior is undergoing a fundamental shift," said Apu Gupta, CEO and co-founder, Curalate. "Increasingly, consumers prefer to engage with brands using pictures rather than words. This is forcing brands to scramble to capitalize on Pinterest. In teaming with ePrize, we're making it incredibly easy for brands to leverage this trend, now."

To learn more about Pinterest promotion opportunities with Curalate and ePrize, please register for a joint webinar on May 2 from 2:00-2:30pm ET: http://www.eprize.com/engage/webinars/

About ePrize ePrize is a global leader in digital and mobile engagement. A majority of Fortune 500 brands such as Coca-Cola, Microsoft, The Gap, MillerCoors, Lenovo, NHL, Yahoo!, P&G and AT&T, have relied on ePrize's multi-channel solutions to engage consumers on their path to purchase -- all on a single unified platform. Since 1999, ePrize has created thousands of promotions, CRM and loyalty campaigns in 44 countries. Headquartered in Detroit, ePrize also has offices in Chicago, Los Angeles, Nashville, New York, Phoenix, San Francisco, and Seattle. Visit us at eprize.com or text CRM to 35350 for mobile demos and alerts. For ePrize's press kit, click here .

About Curalate Headquartered in Philadelphia with offices in NYC, Curalate is the only platform that applies advanced image recognition algorithms to social media conversations to make sense of the visual web, starting with Pinterest and Instagram. Hundreds of the world's leading brands and agencies across multiple sectors, including consumer packaged goods, retail, publishing, luxury, automotive and media have turned to Curalate to help them cultivate more meaningful relationships with consumers and increase sales using visual social media sites. Curalate is backed by top tier venture capitalists including NEA and First Round Capital. For more information please visit: www.curalate.com .

Media Contact: LaunchSquad for ePrize Courtnee Coburn eprize@launchsquad.com 212-564-3665

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Class Action Greenlighted Against Concordia for Title IX Violations

Updated Category News Views 87

Paving the Way for Equality in Campus Sports Ah, courts and colleges—two institutions you'd hope would play by the rules. But here we are, knee-deep in a legal battle with Concordia University Irvine (CUI) caught in the crosshairs of Title IX compliance issues. No surprise there when a federal court finally gave the nod for a class action to plow ahead. Class Action...

Continue Reading
AppLovin Legal Woes: A Deep Dive into Investor Claims

Updated Category News Views 104

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Continue Reading
Microsoft's Cloud Misstep: Recovery Plans in Focus

Updated Category News Views 149

Microsoft's Stumble Puts CIOs on Alert Thursday's Microsoft 365 outage, a wrench in the works for every firm that ties its daily operations to these cloud services, has brought some harsh truths to the table. On November 12, outages hit users hard, preventing access to Exchange Online mailboxes and sending ripples through Teams, SharePoint, Copilot, and Defender. You...

Continue Reading
EFICYENT Ventures to Connect at Singapore FinTech Fest

Updated Category News Views 118

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Continue Reading
Innovent's Seven Drugs Leap onto 2026 Reimbursement Chart

Updated Category News Views 202

A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 162

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Novo's Research Unlocks New Insights into Food Noise

Updated Category News Views 179

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Continue Reading
Maritime Safety Urged After New Orleans Vessel Incident

Updated Category News Views 109

The Mississippi River saw a bit of drama near the Port of New Orleans when a river cruise turned into an unexpected rescue operation. Listen up, because incidents like this bring maritime safety right to the forefront; we can't ignore the waters that shape our daily lives here in the Big Easy. Navigating the Waters Safely Some 150 souls found themselves in a pickle when...

Continue Reading
Windward Bio Surges 68% in Nasdaq Debut

Updated Category News Views 134

Windward Bio's Impressive Nasdaq Debut Well, how's that for a debut? Windward Bio, this buzzing clinical-stage biotechnology firm, hit Nasdaq like a storm on November 13, 2026. They priced their IPO at $17.00 per share, but by market close, the stock sat comfortably at $28.50. That's a hearty 68% jump on day one, putting their market value at a sweet $1.69 billion. Behind...

Continue Reading
Ecopetrol Sidesteps Hefty Fines After Investigation Closure

Updated Category News Views 145

Colombian Watchdog Gives Ecopetrol a Pass It's like dodging a bullet in a duel at high noon. The Superintendency of Industry and Commerce (SIC) has finally closed its investigation into Ecopetrol S.A. and its subsidiaries, CENIT and OCENSA, after a probe two years in the making. The stakes were sky-high, folks. We're talkin' about just shy of 530 billion Colombian pesos...

Continue Reading

Top 5 Most Recently Viewed Articles

Kimbell Royalty Partners Engages Investors at Key Conferences

Updated Category News Views 101

Kimbell Royalty Partners to Attend Notable Investor Conferences Kimbell Royalty Partners, LP (NYSE: KRP) is a prominent owner of oil and natural gas mineral and royalty interests. The company proudly manages over 129,000 gross wells across multiple states. In an effort to strengthen investor relations and share its strategic outlook, Kimbell has announced its...

Continue Reading
Karsan's Autonomous Bus Debuts at Efteling Park

Updated Category News Views 72

A Leap Towards Autonomous Mobility What we have here is Karsan breaking new ground again. They've rolled out their Autonomous e-ATAK at Efteling, the famous theme park in the Netherlands. And that's not just any park—it's a place teeming with tourists, a hotspot demanding efficient transport. Yet, these folks aren't just cranking out fancy gadgets for showing off....

Continue Reading
EyePoint Pharmaceuticals Expands Workforce with Stock Options

Updated Category News Views 301

EyePoint Pharmaceuticals Expands Workforce with Stock Options EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a dynamic biopharmaceutical company, is on a mission to enhance the lives of patients facing serious retinal diseases. Recently, the company made a notable announcement regarding the expansion of its team through the granting of non-statutory stock options to new...

Continue Reading
IonQ Shares: Insights Into Their Current Market Performance

Updated Category News Views 204

Overview of IonQ's Current Stock Performance IonQ Inc. IONQ shares have seen a notable decline recently, continuing a downward trend that’s persisted over the last couple of weeks. As the company gears up to announce its second-quarter earnings, investors are closely monitoring the developments, particularly the anticipated shift in stock momentum. Market Sentiment and...

Continue Reading
Exploring the Promising CD47 Inhibitor Drug Market Growth

Updated Category News Views 40

Understanding the CD47 Inhibitor Drug Market Gaining insights into the CD47 inhibitor drug market is crucial for recognizing the changes and advancements in cancer immunotherapy. These drugs play a vital role in the battle against cancer by harnessing the body's immune system to identify and eliminate malignant cells. CD47's Role in Cancer CD47, often referred to as the...

Continue Reading